Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Survey-weighted association of flavonoids and six subclasses intake with MASLD. by Yuwei He (1565941)

Subjects:

Survey-weighted baseline characteristic of the study population by MASLD. by Yuwei He (1565941)

Subjects:

Weighted Quantile Sum model regression index weights for the MASLD. by Yuwei He (1565941)

Subjects:

The flowchart of the sample selection from NHANES 2007-2010, 2017-2018. by Yuwei He (1565941)

Subjects:

Association between flavonoid intakes and metabolic dysfunction-associated steatotic liver disease (MASLD) using a Restricted Cubic Spline regression model, adjusted for age, sex,... by Yuwei He (1565941)

Subjects:

<i>mMgat2</i> and <i>HuMgat2</i> mice exhibit a transcriptomic profile indicating impairments in metabolite detoxification and lipid metabolic processes. by J. Jose Corbalan (22439198)

Subjects:

Changes in maximal strength within each group after treatment. by Sergio R. Thomaz (20308465)

S2 Appendix - by Shaaista Budhani (21030221)

“…There was a trend of increased recall rates in group 2 for short-term problems, long-term problems, intervention, and incidence rates, but it did not reach statistically significant level. …”

Outcomes and interventions by group comparison. by Shaaista Budhani (21030221)

“…There was a trend of increased recall rates in group 2 for short-term problems, long-term problems, intervention, and incidence rates, but it did not reach statistically significant level. …”

S1 Fig.pdf - by Shaaista Budhani (21030221)

“…There was a trend of increased recall rates in group 2 for short-term problems, long-term problems, intervention, and incidence rates, but it did not reach statistically significant level. …”

Baseline characteristics of participants. by Shaaista Budhani (21030221)

“…There was a trend of increased recall rates in group 2 for short-term problems, long-term problems, intervention, and incidence rates, but it did not reach statistically significant level. …”

Participant enrollment. by Shaaista Budhani (21030221)

“…There was a trend of increased recall rates in group 2 for short-term problems, long-term problems, intervention, and incidence rates, but it did not reach statistically significant level. …”

S1 Appendix - by Shaaista Budhani (21030221)

“…There was a trend of increased recall rates in group 2 for short-term problems, long-term problems, intervention, and incidence rates, but it did not reach statistically significant level. …”

S1 Protocol - by Shaaista Budhani (21030221)

“…There was a trend of increased recall rates in group 2 for short-term problems, long-term problems, intervention, and incidence rates, but it did not reach statistically significant level. …”

Projected global leukemia burden, 1990-2050. by Chengjun Hu (588206)

“…Conclusion: Although there has been a marked decrease in global leukemia incidence, mortality, and DALYs over the past 31 years, the rise in new cases due to population growth suggests an increasing overall disease burden by 2050. …”

Correlation between HDI and EAPC. by Chengjun Hu (588206)

“…Conclusion: Although there has been a marked decrease in global leukemia incidence, mortality, and DALYs over the past 31 years, the rise in new cases due to population growth suggests an increasing overall disease burden by 2050. …”

Global leukemia incidence and EAPC, 1990-2021. by Chengjun Hu (588206)

“…Conclusion: Although there has been a marked decrease in global leukemia incidence, mortality, and DALYs over the past 31 years, the rise in new cases due to population growth suggests an increasing overall disease burden by 2050. …”